Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

AKT signalling selectively regulates PINK1 mitophagy in SHSY5Y cells and human iPSC-derived neurons.

Soutar MPM, Kempthorne L, Miyakawa S, Annuario E, Melandri D, Harley J, O'Sullivan GA, Wray S, Hancock DC, Cookson MR, Downward J, Carlton M, Plun-Favreau H.

Sci Rep. 2018 Jun 11;8(1):8855. doi: 10.1038/s41598-018-26949-6.

2.

The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma.

Miess H, Dankworth B, Gouw AM, Rosenfeldt M, Schmitz W, Jiang M, Saunders B, Howell M, Downward J, Felsher DW, Peck B, Schulze A.

Oncogene. 2018 Jun 5. doi: 10.1038/s41388-018-0315-z. [Epub ahead of print]

PMID:
29872221
3.

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.

Coelho MA, de Carné Trécesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, East P, Spencer-Dene B, Nye E, Barnouin K, Snijders AP, Lai WS, Blackshear PJ, Downward J.

Immunity. 2017 Dec 19;47(6):1083-1099.e6. doi: 10.1016/j.immuni.2017.11.016. Epub 2017 Dec 12.

4.

An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.

Mancini M, Gal H, Gaborit N, Mazzeo L, Romaniello D, Salame TM, Lindzen M, Mahlknecht G, Enuka Y, Burton DG, Roth L, Noronha A, Marrocco I, Adreka D, Altstadter RE, Bousquet E, Downward J, Maraver A, Krizhanovsky V, Yarden Y.

EMBO Mol Med. 2018 Feb;10(2):294-308. doi: 10.15252/emmm.201708076.

5.

Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor.

Mathew G, Hannan A, Hertzler-Schaefer K, Wang F, Feng GS, Zhong J, Zhao JJ, Downward J, Zhang X.

Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13156-13161. Epub 2016 Oct 31.

6.

Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer.

Li H, Stokes W, Chater E, Roy R, de Bruin E, Hu Y, Liu Z, Smit EF, Heynen GJ, Downward J, Seckl MJ, Wang Y, Tang H, Pardo OE.

Cell Discov. 2016 Sep 27;2:16031. eCollection 2016.

7.

HF-Free Boc Synthesis of Peptide Thioesters for Ligation and Cyclization.

Raz R, Burlina F, Ismail M, Downward J, Li J, Smerdon SJ, Quibell M, White PD, Offer J.

Angew Chem Int Ed Engl. 2016 Oct 10;55(42):13174-13179. doi: 10.1002/anie.201607657.

8.

Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3Kβ in myeloid cells.

Houslay DM, Anderson KE, Chessa T, Kulkarni S, Fritsch R, Downward J, Backer JM, Stephens LR, Hawkins PT.

Sci Signal. 2016 Aug 16;9(441):ra82. doi: 10.1126/scisignal.aae0453.

9.

RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression.

Castellano E, Molina-Arcas M, Krygowska AA, East P, Warne P, Nicol A, Downward J.

Nat Commun. 2016 Apr 13;7:11245. doi: 10.1038/ncomms11245.

10.

Tumour-suppression function of KLF12 through regulation of anoikis.

Godin-Heymann N, Brabetz S, Murillo MM, Saponaro M, Santos CR, Lobley A, East P, Chakravarty P, Matthews N, Kelly G, Jordan S, Castellano E, Downward J.

Oncogene. 2016 Jun 23;35(25):3324-34. doi: 10.1038/onc.2015.394. Epub 2015 Oct 12.

11.

Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach.

Pender A, Garcia-Murillas I, Rana S, Cutts RJ, Kelly G, Fenwick K, Kozarewa I, Gonzalez de Castro D, Bhosle J, O'Brien M, Turner NC, Popat S, Downward J.

PLoS One. 2015 Sep 28;10(9):e0139074. doi: 10.1371/journal.pone.0139074. eCollection 2015.

12.

Overview of KRAS-Driven Genetically Engineered Mouse Models of Non-Small Cell Lung Cancer.

Sheridan C, Downward J.

Curr Protoc Pharmacol. 2015 Sep 1;70:14.35.1-16. doi: 10.1002/0471141755.ph1435s70. Review.

PMID:
26331885
13.

Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer.

Mancini M, Gaborit N, Lindzen M, Salame TM, Dall'Ora M, Sevilla-Sharon M, Abdul-Hai A, Downward J, Yarden Y.

Sci Signal. 2015 Jun 2;8(379):ra53. doi: 10.1126/scisignal.aaa0725.

PMID:
26038598
14.

RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

Downward J.

Clin Cancer Res. 2015 Apr 15;21(8):1802-9. doi: 10.1158/1078-0432.CCR-14-2180. Review.

15.

RAS mutation status and bortezomib therapy for relapsed multiple myeloma.

Smith D, Armenteros E, Percy L, Kumar M, Lach A, Herledan G, Stubbs M, Downward J, Yong K.

Br J Haematol. 2015 Jun;169(6):905-8. doi: 10.1111/bjh.13258. Epub 2015 Jan 12. No abstract available.

PMID:
25580780
16.

ASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1.

Wang Y, Bu F, Royer C, Serres S, Larkin JR, Soto MS, Sibson NR, Salter V, Fritzsche F, Turnquist C, Koch S, Zak J, Zhong S, Wu G, Liang A, Olofsen PA, Moch H, Hancock DC, Downward J, Goldin RD, Zhao J, Tong X, Guo Y, Lu X.

Nat Cell Biol. 2014 Nov;16(11):1092-104. doi: 10.1038/ncb3050. Epub 2014 Oct 26.

PMID:
25344754
17.

Guidelines for the use of cell lines in biomedical research.

Geraghty RJ, Capes-Davis A, Davis JM, Downward J, Freshney RI, Knezevic I, Lovell-Badge R, Masters JR, Meredith J, Stacey GN, Thraves P, Vias M; Cancer Research UK.

Br J Cancer. 2014 Sep 9;111(6):1021-46. doi: 10.1038/bjc.2014.166. Epub 2014 Aug 12.

18.

RAS interaction with PI3K p110α is required for tumor-induced angiogenesis.

Murillo MM, Zelenay S, Nye E, Castellano E, Lassailly F, Stamp G, Downward J.

J Clin Invest. 2014 Aug;124(8):3601-11. doi: 10.1172/JCI74134. Epub 2014 Jul 8.

19.

Chromosomal instability selects gene copy-number variants encoding core regulators of proliferation in ER+ breast cancer.

Endesfelder D, Burrell R, Kanu N, McGranahan N, Howell M, Parker PJ, Downward J, Swanton C, Kschischo M.

Cancer Res. 2014 Sep 1;74(17):4853-4863. doi: 10.1158/0008-5472.CAN-13-2664. Epub 2014 Jun 26.

20.

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.

de Bruin EC, Cowell C, Warne PH, Jiang M, Saunders RE, Melnick MA, Gettinger S, Walther Z, Wurtz A, Heynen GJ, Heideman DA, Gómez-Román J, García-Castaño A, Gong Y, Ladanyi M, Varmus H, Bernards R, Smit EF, Politi K, Downward J.

Cancer Discov. 2014 May;4(5):606-19. doi: 10.1158/2159-8290.CD-13-0741. Epub 2014 Feb 17.

21.

RAS's cloak of invincibility slips at last?

Downward J.

Cancer Cell. 2014 Jan 13;25(1):5-6. doi: 10.1016/j.ccr.2013.12.016.

22.

HMGA2 functions as a competing endogenous RNA to promote lung cancer progression.

Kumar MS, Armenteros-Monterroso E, East P, Chakravorty P, Matthews N, Winslow MM, Downward J.

Nature. 2014 Jan 9;505(7482):212-7. doi: 10.1038/nature12785. Epub 2013 Dec 4. Retraction in: Nature. 2015 Jul 16;523(7560):370.

23.

Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance.

Castellano E, Sheridan C, Thin MZ, Nye E, Spencer-Dene B, Diefenbacher ME, Moore C, Kumar MS, Murillo MM, Grönroos E, Lassailly F, Stamp G, Downward J.

Cancer Cell. 2013 Nov 11;24(5):617-30. doi: 10.1016/j.ccr.2013.09.012.

24.

Regulation of polarized morphogenesis by protein kinase C iota in oncogenic epithelial spheroids.

Linch M, Sanz-Garcia M, Rosse C, Riou P, Peel N, Madsen CD, Sahai E, Downward J, Khwaja A, Dillon C, Roffey J, Cameron AJ, Parker PJ.

Carcinogenesis. 2014 Feb;35(2):396-406. doi: 10.1093/carcin/bgt313. Epub 2013 Sep 26.

25.

SnapShot: Class I PI3K isoform signaling.

Fritsch R, Downward J.

Cell. 2013 Aug 15;154(4):940-940.e1. doi: 10.1016/j.cell.2013.07.045. No abstract available.

26.

RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms.

Fritsch R, de Krijger I, Fritsch K, George R, Reason B, Kumar MS, Diefenbacher M, Stamp G, Downward J.

Cell. 2013 May 23;153(5):1050-63. doi: 10.1016/j.cell.2013.04.031.

27.

PI3K pathway dependencies in endometrioid endometrial cancer cell lines.

Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J.

Clin Cancer Res. 2013 Jul 1;19(13):3533-44. doi: 10.1158/1078-0432.CCR-12-3815. Epub 2013 May 14.

28.

Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.

Molina-Arcas M, Hancock DC, Sheridan C, Kumar MS, Downward J.

Cancer Discov. 2013 May;3(5):548-63. doi: 10.1158/2159-8290.CD-12-0446. Epub 2013 Mar 1.

29.

Inhibiting the RAS-PI3K pathway in cancer therapy.

Sheridan C, Downward J.

Enzymes. 2013;34 Pt. B:107-36. doi: 10.1016/B978-0-12-420146-0.00005-6. Epub 2013 Nov 7. Review.

PMID:
25034102
30.

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.

Weigelt B, Downward J.

Front Oncol. 2012 Aug 31;2:109. doi: 10.3389/fonc.2012.00109. eCollection 2012.

31.

Frank-ter Haar syndrome protein Tks4 regulates epidermal growth factor-dependent cell migration.

Bögel G, Gujdár A, Geiszt M, Lányi Á, Fekete A, Sipeki S, Downward J, Buday L.

J Biol Chem. 2012 Sep 7;287(37):31321-9. doi: 10.1074/jbc.M111.324897. Epub 2012 Jul 24.

32.

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.

Steckel M, Molina-Arcas M, Weigelt B, Marani M, Warne PH, Kuznetsov H, Kelly G, Saunders B, Howell M, Downward J, Hancock DC.

Cell Res. 2012 Aug;22(8):1227-45. doi: 10.1038/cr.2012.82. Epub 2012 May 22.

33.

The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.

Kumar MS, Hancock DC, Molina-Arcas M, Steckel M, East P, Diefenbacher M, Armenteros-Monterroso E, Lassailly F, Matthews N, Nye E, Stamp G, Behrens A, Downward J.

Cell. 2012 Apr 27;149(3):642-55. doi: 10.1016/j.cell.2012.02.059.

34.

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C.

N Engl J Med. 2012 Mar 8;366(10):883-892. doi: 10.1056/NEJMoa1113205. Erratum in: N Engl J Med. 2012 Sep 6;367(10):976.

35.

How to fool a wonder drug: truncate and dimerize.

Molina-Arcas M, Downward J.

Cancer Cell. 2012 Jan 17;21(1):7-9. doi: 10.1016/j.ccr.2011.12.017.

36.
37.

Assessing cell size and cell cycle regulation in cells with altered TOR activity.

Cully M, Downward J.

Methods Mol Biol. 2012;821:227-37. doi: 10.1007/978-1-61779-430-8_13.

PMID:
22125068
38.

CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction.

Lee AJ, Roylance R, Sander J, Gorman P, Endesfelder D, Kschischo M, Jones NP, East P, Nicke B, Spassieva S, Obeid LM, Birkbak NJ, Szallasi Z, McKnight NC, Rowan AJ, Speirs V, Hanby AM, Downward J, Tooze SA, Swanton C.

J Pathol. 2012 Feb;226(3):482-94. doi: 10.1002/path.2998. Epub 2011 Oct 19.

PMID:
21953249
39.

Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer.

Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I, Hanby AM, Speirs V, Richardson AL, Birkbak NJ, Eklund AC, Downward J, Kschischo M, Szallasi Z, Swanton C.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2183-94. doi: 10.1158/1055-9965.EPI-11-0343. Epub 2011 Jul 22.

40.

RAS Interaction with PI3K: More Than Just Another Effector Pathway.

Castellano E, Downward J.

Genes Cancer. 2011 Mar;2(3):261-74. doi: 10.1177/1947601911408079.

41.

An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis.

Lara R, Mauri FA, Taylor H, Derua R, Shia A, Gray C, Nicols A, Shiner RJ, Schofield E, Bates PA, Waelkens E, Dallman M, Lamb J, Zicha D, Downward J, Seckl MJ, Pardo OE.

Oncogene. 2011 Aug 11;30(32):3513-21. doi: 10.1038/onc.2011.61. Epub 2011 Mar 21.

PMID:
21423205
42.

Targeting RAF: trials and tribulations.

Downward J.

Nat Med. 2011 Mar;17(3):286-8. doi: 10.1038/nm0311-286. No abstract available.

PMID:
21383738
43.

Chromosomal instability confers intrinsic multidrug resistance.

Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, Downward J, Szallasi Z, Tomlinson IP, Howell M, Kschischo M, Swanton C.

Cancer Res. 2011 Mar 1;71(5):1858-70. doi: 10.1158/0008-5472.CAN-10-3604.

44.

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.

Weigelt B, Warne PH, Downward J.

Oncogene. 2011 Jul 21;30(29):3222-33. doi: 10.1038/onc.2011.42. Epub 2011 Feb 28.

PMID:
21358673
45.

Praf2 is a novel Bcl-xL/Bcl-2 interacting protein with the ability to modulate survival of cancer cells.

Vento MT, Zazzu V, Loffreda A, Cross JR, Downward J, Stoppelli MP, Iaccarino I.

PLoS One. 2010 Dec 20;5(12):e15636. doi: 10.1371/journal.pone.0015636.

46.

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets.

Swanton C, Larkin JM, Gerlinger M, Eklund AC, Howell M, Stamp G, Downward J, Gore M, Futreal PA, Escudier B, Andre F, Albiges L, Beuselinck B, Oudard S, Hoffmann J, Gyorffy B, Torrance CJ, Boehme KA, Volkmer H, Toschi L, Nicke B, Beck M, Szallasi Z.

Genome Med. 2010 Aug 11;2(8):53. doi: 10.1186/gm174.

47.

PI3-kinase p110α mediates β1 integrin-induced Akt activation and membrane protrusion during cell attachment and initial spreading.

Zeller KS, Idevall-Hagren O, Stefansson A, Velling T, Jackson SP, Downward J, Tengholm A, Johansson S.

Cell Signal. 2010 Dec;22(12):1838-48. doi: 10.1016/j.cellsig.2010.07.011. Epub 2010 Jul 25. Erratum in: Cell Signal. 2012 Apr;24(4):971-2.

PMID:
20667469
48.

Role of RAS in the regulation of PI 3-kinase.

Castellano E, Downward J.

Curr Top Microbiol Immunol. 2010;346:143-69. doi: 10.1007/82_2010_56. Review.

PMID:
20563706
49.

Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells.

Wang Y, Ngo VN, Marani M, Yang Y, Wright G, Staudt LM, Downward J.

Oncogene. 2010 Aug 19;29(33):4658-70. doi: 10.1038/onc.2010.218. Epub 2010 Jun 21.

PMID:
20562906
50.

Modulation of cellular migration and survival by c-Myc through the downregulation of urokinase (uPA) and uPA receptor.

Alfano D, Votta G, Schulze A, Downward J, Caputi M, Stoppelli MP, Iaccarino I.

Mol Cell Biol. 2010 Apr;30(7):1838-51. doi: 10.1128/MCB.01442-09. Epub 2010 Feb 1.

Supplemental Content

Loading ...
Support Center